The WHO guidelines recommend treating people with DS-TB with a 6-month regimen composed of four first-line TB medicines: isoniazid, rifampicin, pyrazinamide and ethambutol (1). The …

• Standard anti-tuberculosis regimen of 2EHRZ/4HR should be used in the treatment of pulmonary tuberculosis (PTB). • Only daily anti-tuberculosis regimen should be used …

In 2021, a 4-month regimen comprising INH, pyrazinamide (PZA, Z), rifapentine (P) and moxifloxacin (Mfx) was shown to be non-inferior to the standard 6-month DS-TB regimen. 14 …

Since 2010, the WHO guidelines have recommended treating persons with DS-TB with a 6-month regimen composed of four first line TB medicines – isoniazid, rifampicin, ethambutol and …

Patients with a large bacillary load (sputum smear-positive pulmonary TB and many HIV-infected patients with smear-negative pulmonary TB) have an increased risk of selecting resistant …

2HRZE/4HR = initial phase of 2 months of isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E), followed by continuation phase of 4 months of isoniazid and rifampicin; ATS = …

rifampicin (2HRZE/4HR) will reduce the number of relapses and failures. This will alleviate patient suffering resulting from a second episode of tuberculosis (TB) and conserve patient and …

• In children and adolescents between 3 months and 16 years of age with non-severe TB (without suspicion or evidence of MDR/RR-TB), a 4-month treatment regimen (2HRZ(E)/2HR) should …

Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin …

Dec 4, 2024 · Presently, a 6-month regimen consisting of 2 months of daily (intensive regimen) EHRZ (2EHRZ) followed by 4 months of daily (maintenance regimen) HR (4HR) is the …